U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Javier Revollo
  1. Science & Research (NCTR)

Javier Revollo Ph.D.

Research Biologist — Division of Genetic and Molecular Toxicology

Headshot of Dr. Javier Revollo

Javier Revollo, Ph.D.
(870) 543-7121
NCTRResearch@fda.hhs.gov  

Back to NCTR Principal Investigators page

About  |  Publications  |  Lab Member

Background

Javier Revollo is a research biologist and principial investigator in the Division of Genetic and Molecular Toxicology at FDA’s National Center for Toxicological Research (NCTR). He studied at the University of Wisconsin-Madison, receiving a B.S. degree in genetics, and Washington University in St. Louis, where he earned a Ph.D. in molecular cell biology. He then pursued postdoctoral studies at the National Institutes of Health. Javier joined the FDA as a commissioner’s fellow due to his expertise in genomics, DNA sequencing, and bioinformatics. His research efforts at FDA have focused on the development of DNA sequencing methods and bioinformatic algorithms to study somatic mutations.

Research Interests

Dr. Revollo is developing error-corrected sequencing methods and bioinformatic algorithms capable of directly identifying somatic mutations from DNA samples. Many of these tools have been used to:

  • Validate the “Mammalian Erythrocyte Pig-a Gene Mutation Assay” (OECD Test Guideline No. 470)
  • Study chemicals difficult to evaluate by conventional mutation detection assays (e.g., nitrosamines)
  • Study mutagenesis in microphysiological systems, where conventional mutation detection assays cannot be implemented
  • Identify off-target mutations created by genome editing
     

Selected Publications

Assessment of In Vivo Chemical Mutagenesis by Long-Read Sequencing.
Miranda J.A. and Revollo J.R.
Toxicological Sciences. 2024, doi: 10.1093/toxsci/kfae104. Epub 2024 Aug 14.

Unbiased Whole Genome Detection of Ultrarare Off-Target Mutations in Genome-Edited Cell Populations by HiFi Sequencing.
Miranda J.A., Fenner K., McKinzie P.B., Dobrovolsky V.N., and Revollo J.R.
Environ Mol Mutagen. 2023, 64(7):374-381. doi: 10.1002/em.22566. Epub 2023 Aug 11.

Evaluation of the Mutagenic Effects of Molnupiravir and N4-Hydroxycytidine in Bacterial and Mammalian Cells by HiFi Sequencing.
Miranda J.A., McKinzie P.B., Dobrovolsky V.N., and Revollo J.R.
Environ Mol Mutagen. 2022, 63(7):320-328. doi: 10.1002/em.22510. Epub 2022 Oct 25.

Genome-Wide Detection of Ultralow-Frequency Substitution Mutations in Cultures of Mouse Lymphoma L5178Y Cells and Caenorhabditis elegans Worms by PacBio Sequencing.
Miranda J.A., Alund A.W., Yan J., McKinzie P.B., Dobrovolsky V.N., and Revollo J.R.
Environ Mol Mutagen. 2022, 63(2):68-75. doi: 10.1002/em.22473. Epub 2022 Mar 12.

PacBio Sequencing Detects Genome-Wide Ultra-Low-Frequency Substitution Mutations Resulting from Exposure to Chemical Mutagens.
Revollo J.R., Miranda J.A., and Dobrovolsky V.N.
Environ Mol Mutagen. 2021, 62(8):438-445. doi: 10.1002/em.22462. Epub 2021 Sep 2.

Targeting Specificity of APOBEC-Based Cytosine Base Editor in Human iPSCs Determined by Whole Genome Sequencing.
McGrath E., Shin H., Zhang L., Phue J.N., Wu W.W., Shen R.F., Jang Y.Y., Revollo J., and Ye Z.
Nat Commun. 2019, 10(1):5353. doi: 10.1038/s41467-019-13342-8.

Lab Member

Contact information for all lab members:
(870) 543-7121
NCTRResearch@fda.hhs.gov

Jaime Miranda, B.S.
Biologist
 

Contact Information
Javier Revollo
(870) 543-7121
Expertise
Expertise
Approach
Domain
Technology & Discipline
Toxicology
Back to Top